Document is current

Article History

Received: 20 July 2021

Accepted: 18 April 2022

First Online: 3 June 2022

Competing interests

: A.M. is an equity holder in Elucid Bioimaging and in Inspirata Inc. He is also a scientific advisory consultant for Aiforia Inc. In addition, he has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol-Myers-Squibb and Merck. He also has sponsored research agreements with Philips, Astrazeneca, Bristol-Myers Squibb, and Boehringer-Ingelheim. His technology has been licensed to Elucid Bioimaging and Inspirata Inc. He is also involved in a NIH U24 grant with PathCore Inc, and three different R01 grants with Inspirata Inc. K.S. received research funding from Genoptix/Navigate (Novartis), Tesaro, Moderna Therapeutics, Takeda, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol-Myers Squibb, AstraZeneca and Eli Lilly. In addition, he has received honoraria for consultant/advisory roles from Celgene, Moderna Therapeutics, Shattuck Labs, Pierre-Fabre, AstraZeneca, EMD Serono, Ono Pharmaceuticals, Clinica Alemana de Santiago, Dynamo Therapeutics, PeerView, Abbvie, Fluidigm, Takeda/Millenium Pharmaceuticals, Merck, Bristol-Myers Squibb, Agenus and Torque Therapeutics. D.L.R. has served as a scientific advisory board member for Amgen, Astra Zeneca, Cell Signaling Technology, Cepheid, Daiichi Sankyo, Danaher, GSK, Konica/Minolta, Merck, NanoString, Perkin Elmer, PAIGE.AI, Roche, Ventana, and Ultivue. He is also a scientific advisory consultant for NextCure, and Odonate, Sanofi. Additionally, he received research funding from Amgen, Cepheid, Navigate, NextCure, Konica/Minolta, Lily, Ultivue, and received instrutment support from Ventana, Akoya/Perkin Elmer, and NanoString. He also received travel funding from Astra Zeneca and receives royalty support from Rarecyte. He is also the founder and equity holder of PixelGear. N.B. is currently an employee of Tempus Labs, Inc. Vipul Baxi, David Balli, and Merzu Belete are currently employees of Bristol-Myers Squibb. S.B. received research funding from Roche and Basilea (to institution), and has served as a scientific advisory board member for Eli Lilly. The remaining authors declare no competing interests.